AdBio partners
Venture capitalParis · Pre-Seed–Series A · 21 people tracked
Investment thesis
AdBio Partners invests in and develops early-stage life sciences startups across Europe, targeting the most promising therapeutic innovations across various therapeutic areas. Combining business, scientific, and financial expertise, the firm positions itself as both entrepreneurs and investors, sourcing breakthrough medical discoveries and building sustainable startups alongside scientific founders and academic institutions. It works with leading research institutions and technology transfer offices, supported by a network of scientific and industrial partners and international VC syndicates.
Source: firm website, verified Aug 3, 2026.
Team · 21 people
from the firm's website & public directories
What they invest in
from 16 of 42 portfolio companiesBiotech ×15Healthtech ×11Medical Devices ×6Deep Tech ×4Digital Health ×2Gaming ×1Longevity ×1
HQs:France×5Belgium×1Spain×1United States×1
Investments · 42 tracked
founders shown can be your intro pathAndzonBio operates a suite of thematic "pipeline builder" studios that accelerate the industrial development of academic life sciences projects into biotech companies, focusing on specific therapeutic areas such as cardiovascular/renal/metabolic disorders and neurological disorders.
BiotechDeep TechHealthtech
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)Jean-Pascal Tranié(Co-Founder)
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting fibro-inflammation, with a focus on treating fibrotic diseases including Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis.
BiotechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
A suite of thematic Pipeline Builder Companies accelerating industrial development of promising academic biotech projects.
First thematic Pipeline Builder Company from the AndzonBio initiative, accelerating academic projects in cardiovascular, renal and metabolic (CVRM) disorders.
Andzon Bio develops breakthrough therapeutic programs targeting core disease mechanisms of underserved cardiovascular, renal, and metabolic (CVRM) conditions.
BiotechHealthtechParis, FR
Second thematic Pipeline Builder Company from the AndzonBio initiative, dedicated to neuroinflammation.
AndzonBio2 develops early-stage, mechanism-based therapies targeting neuroinflammation as a driver of neurological and neurodegenerative diseases.
BiotechHealthtech
Develops a disease-modifying approach in Cystic Fibrosis.
Clinical-stage biotech developing medicines through modulation of microRNAs; lead compound is ATX-01.
Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease.
BiotechMedical Devices
Developing The Benchtop Cell Factory, an end-to-end platform for Cell and Gene Therapy manufacturing using microfluidic technology.
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Develops a first-in-class approach to thrombo-inflammation and vascular diseases.
Molecular diagnostics company offering clinical PCR systems using automation and microfluidics; acquired by QIAGEN in September 2020.
BiotechHealthtechAlbuquerque, US
Thomas Duensing(Executive Officer)Dennis Hynson(Executive Officer)Jack T. Ball(Director)J. Michael Schafer(Director)Janette Phi(Executive Officer)Bo E.H. Saxberg(Director)
Develops first-in-class KATP channel inhibitors for migraine treatment.
Cephagenix is a biotech company working on identifying and developing new treatments for migraine.
BiotechHealthtechParis, FR
Develops novel immune oncology agents for tumour-selective modulation of the microenvironment.
Developing first-in-class recombinant proteins for the treatment of type 1 diabetes.
Develops a first-in-class anti-FGFR4 mAb for cardiorenal disorders.
Develops first-in-class antibodies targeting calcium signaling for auto-immune diseases.
Developing IPSC-MSC engineered cell therapy for inflammatory diseases.
KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction.
BiotechHealthtechMedical Devices
Miguel Forte(CEO)Tony Ting(CSO)Michel Andraud(CFO)Yen Wu(CBO)
Advancing engineered cytokines for the treatment of immune-mediated diseases.
Orikine Bio develops precision-engineered bi-specific cytokine therapies ("Foldikines") that reprogram immune signaling to treat severe autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechBarcelona, ES
Larry Edwards(Chairman of the Board)
Developing small molecules targeting the eIF4F complex in cancer.
The page promotes an online gambling/betting brand ("regalbet") presented as a digital gaming platform, using SEO-style marketing text targeting players in large cities.
Gaming
Develops gene therapy treatments for Inherited Retinal Diseases regardless of genetic cause.
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.
BiotechDigital HealthHealthtechLongevityMedical Devices
Develops monoclonal antibody treatments for human mucosal inflammatory diseases.
Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody that targets extracellular AGR2 to treat inflammatory mucosal diseases.
BiotechMedical Devices
Develops first-in-class CD31-ITAM immune modulating bispecific antibodies for auto-immune and inflammatory disorders.
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Developing a structure-based drug discovery platform for readthrough compounds to treat cancer and rare diseases.
Urania Therapeutics develops treatments for genetic diseases and cancers caused by nonsense mutations, targeting monogenic diseases in which a single gene defect impairs production of a functional protein.
BiotechHealthtech
Develops small molecules inhibiting the non-canonical NF-κB2 pathway for cancer treatment.
Frequently asked questions
- What stage does AdBio partners invest at?
- AdBio partners invests at the Pre-Seed, Seed, Series A stages.
- What sectors does AdBio partners focus on?
- AdBio partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is AdBio partners located?
- AdBio partners is headquartered in Paris, FR.
Similar investors
Future Positive Capital is an investment firm backing entrepreneurs building companies that address major global challenges and shape more sustainable, preferable futures.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.